Comparison · NCT00096278-sae
Oxaliplatin + Leucovorin + 5-Fluorouracil vs Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Oxaliplatin + Leucovorin + 5-Fluorouracil vs Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab: serious adverse events. Trial comparisons, record NCT00096278-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00096278-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0611 | 0.0494 | 0.0753 | wilson | |
| Risk in group 2 | 0.202 | 0.182 | 0.225 | wilson | |
| Risk difference, group 1 minus group 2 | -0.141 | -0.167 | -0.116 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.302 | 0.238 | 0.382 | log | |
| Odds ratio, group 1 over group 2 | 0.256 | 0.197 | 0.333 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Oxaliplatin + Leucovorin + 5-Fluorouracil than on Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 7.08 | 6 | 8.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Oxaliplatin + Leucovorin + 5-Fluorouracil | Oxaliplatin + Leucovorin + 5-Fluorouracil | 81 | 1,326 | EG000 |
| Group 2 | Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab | 270 | 1,334 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
- NCT number
- NCT00096278
- Phases
- PHASE3
- Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7
- Interventions
- Bevacizumab, Fluorouracil, Leucovorin Calcium, Oxaliplatin
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2012-12-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00096278?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00096278-sae